@secretszawl's GLP-1 claims need a closer look

What did @secretszawl actually say?

Straightforwardly: nothing about GLP-1 medications. The transcript captured here is song lyrics, specifically "Fast forward to go down on me / You come alive because I love." There is no medical claim, no weight loss tip, no semaglutide advice. This video was categorized under GLP-1 content, but the audio does not contain any health information whatsoever. That matters, because 208,500 people watched it under that category label.

It is possible the video was mistagged algorithmically, or that the creator used a trending audio clip over unrelated visual content. Without seeing the visuals, we cannot rule out that on-screen text made GLP-1 claims the transcript does not capture. But based solely on what was said, there is nothing to fact-check in the traditional sense.

Does the science back this up?

There is no scientific claim here to evaluate. Song lyrics are not medical advice, and we are not going to pretend otherwise. However, since this video reached over 200,000 viewers in a GLP-1 context, it is worth addressing what actually does have scientific backing in this medication category, so the audience who arrived here expecting GLP-1 content gets something useful.

GLP-1 receptor agonists like semaglutide and tirzepatide have strong clinical trial data behind them. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide produced up to 22.5% mean body weight reduction over 72 weeks. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4mg produced approximately 14.9% weight loss versus 2.4% with placebo. These are not trivial numbers. But they come from controlled trials, not TikTok videos with pop song overlays.

What did they get wrong (or right)?

The creator did not get anything medically wrong, because they did not say anything medical. That is not a compliment. A video reaching 208,500 people in the GLP-1 category that contains zero health information is a missed opportunity at best, and a potential source of confusion at worst. Viewers searching for legitimate GLP-1 guidance deserve content that actually addresses their questions.

What is concerning is the broader pattern this represents. Health content categories on short-form video platforms frequently get populated by tangentially related or entirely unrelated videos. When someone navigating a new medication decision lands on content like this, they get nothing actionable. The absence of misinformation here is not the same as the presence of useful information. Both outcomes can leave patients worse off than they should be.

What should you actually know?

If you found this video because you are researching GLP-1 medications, here is what the evidence actually says. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are FDA-approved medications with meaningful clinical trial support for weight management and type 2 diabetes. They are not identical. Tirzepatide acts on both GIP and GLP-1 receptors, while semaglutide acts on GLP-1 receptors alone. That pharmacological difference translates to different efficacy and side effect profiles in real patients.

Compounded versions of these drugs are not the same as FDA-approved brand-name products. The FDA has issued warnings about compounded semaglutide quality and dosing consistency. Anyone considering these medications should be working with a licensed prescriber who reviews their full medical history, not making decisions based on social media content, categorized correctly or not.

• GLP-1 medications require a prescription and medical supervision.
• Side effects including nausea, vomiting, and gastroparesis risk are real and should be discussed with a provider.
• Stopping these medications abruptly is associated with weight regain in most patients (Wilding et al., 2022, Diabetes, Obesity and Metabolism).